Meritain Health policies

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

74 policies name 96368, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Health policies
PolicyDetailsCodesSource
0938-Ketamine for the Treatment of Depression and Other Selected Indications0938 · Commercial3Original policy ↗
0951-Brexanolone (Zulresso)0951 · Commercial3Original policy ↗
0976-Plasminogen, Human-tvmh (Ryplazim)0976 · Commercial3Original policy ↗
1005-Tebentafusp-tebn (Kimmtrak)1005 · Commercial5Original policy ↗
Denileukin Diftitox-cxdl (Lymphir)1070 · Commercial5Original policy ↗
0709-Nesiritide (Natrecor)0709 · Commercial7Original policy ↗
0982-Remdesivir (Veklury)0982 · Commercial7Original policy ↗
1001-Sirolimus Protein-Bound Particles for Injectable Suspension Albumin-Bound (Fyarro)1001 · Commercial7Original policy ↗
1052-Exagamglogene Autotemcel (Casgevy)1052 · Commercial8Original policy ↗
1053-Lovotibeglogene Autotemcel (Lyfgenia)1053 · Commercial8Original policy ↗
0920-Tisagenlecleucel (Kymriah)0920 · Commercial9Original policy ↗
0949-Caplacizumab-yhdp (Cablivi)0949 · Commercial10Original policy ↗
0989-Evinacumab-dgnb (Evkeeza)0989 · Commercial10Original policy ↗
1019-Tremelimumab-actl (Imjudo)1019 · Commercial10Original policy ↗
1021-Mirvetuximab Soravtansine-gynx (Elahere)1021 · Commercial10Original policy ↗
0868-Decitabine0868 · Commercial11Original policy ↗
0889-Levoleucovorin (Khapzory)0889 · Commercial12Original policy ↗
0936-Ibalizumab-uiyk (Trogarzo)0936 · Commercial12Original policy ↗
0524-Zoledronic Acid0524 · Commercial13Original policy ↗
Coronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions0491 · Commercial13Original policy ↗
Hereditary Angioedema0782 · Commercial14Original policy ↗
0234-Chelation Therapy0234 · Commercial15Original policy ↗
1048-Mirikizumab-mrkz (Omvoh)1048 · Commercial15Original policy ↗
0834-Paclitaxel, Albumin-Bound0834 · Commercial16Original policy ↗
1006-Sutimlimab-jome (Enjaymo)1006 · Commercial17Original policy ↗
1018-Teclistamab-cqyv (Tecvayli)1018 · Commercial17Original policy ↗
Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD)0911 · Commercial17Original policy ↗
Neonatal Hyperbilirubinemia0332 · Commercial17Original policy ↗
0748-Panitumumab (Vectibix)0748 · Commercial18Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
0996-Aducanumab-avwa (Aduhelm)0996 · Commercial20Original policy ↗
1026-Lecanemab-irmb (Leqembi)1026 · Commercial21Original policy ↗
Donanemab-azbt (Kisunla)1066 · Commercial21Original policy ↗
1097-Etuvetidigene Autotemcel (Waskyra)1097 · Commercial22Original policy ↗
0939-Transthyretin-Mediated (ATTR) Amyloidosis0939 · Commercial25Original policy ↗
1099-Narsoplimab-wuug (Yartemlea)1099 · Commercial25Original policy ↗
0751-Natalizumab0751 · Commercial26Original policy ↗
1060-Fidanacogene Elaparvovec-dzkt (Beqvez)1060 · Commercial27Original policy ↗
1013-Spesolimab-sbzo (Spevigo)1013 · Commercial28Original policy ↗
Intravenous Iron Therapy0575 · Commercial28Original policy ↗
0915-Nusinersen (Spinraza)0915 · Commercial30Original policy ↗
0810-Gout0810 · Commercial34Original policy ↗
1037-Valoctocogene Roxaparvovec-rvox (Roctavian) - CPB 10361037 · Commercial35Original policy ↗
Pegzilarginase-nbln (Loargys)1101 · Commercial35Original policy ↗
Pemetrexed Products0687 · Commercial35Original policy ↗
0845-Carfilzomib (Kyprolis)0845 · Commercial38Original policy ↗
0997-Anifrolumab-fnia (Saphnelo)0997 · Commercial38Original policy ↗
0024-Aldesleukin (Proleukin)0024 · Commercial39Original policy ↗
0905-Secukinumab (Cosentyx)0905 · Commercial39Original policy ↗
1023-Etranacogene Dezaparvovec-drlb (Hemgenix)1023 · Commercial41Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.